Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 698Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4Ozurdex

02 1Ozurdex?

03 1Tobramycin/ Dexamethasone

PharmaCompass

02

Brand Name : Ozurdex

arrow
2024 ACI Convention
Not Confirmed

Dexamethasone

Main Therapeutic Indication : Ophthalmology

Currency : USD

2017 Revenue in Millions : 312

2016 Revenue in Millions : 263

Growth (%) : 18

Abbvie CB

03

Brand Name : Ozurdex

arrow
2024 ACI Convention
Not Confirmed

Dexamethasone

Main Therapeutic Indication : Ophthalmology

Currency : USD

2018 Revenue in Millions : 299

2017 Revenue in Millions : 312

Growth (%) : -4%

Abbvie CB

04

Brand Name : Ozurdex

arrow
2024 ACI Convention
Not Confirmed

Dexamethasone

Main Therapeutic Indication : Ophthalmology

Currency : USD

2016 Revenue in Millions : 263

2015 Revenue in Millions : 168

Growth (%) : 57

Abbvie CB

05

Brand Name : Ozurdex?

arrow
2024 ACI Convention
Not Confirmed

Dexamethasone

Main Therapeutic Indication : Ophthalmology

Currency : USD

2019 Revenue in Millions : 400

2018 Revenue in Millions : 299

Growth (%) : 34

Abbvie CB

06

Brand Name : Tobramycin/ Dexamethasone

Dexamethasone

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Tobramycin/ Dexamethasone

arrow
2024 ACI Convention
Not Confirmed

Dexamethasone

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 33

2019 Revenue in Millions : 31

Growth (%) : 6

blank